Phase 2
N=39
Lexapro and Pramipexole and to Treat Major Depression
Major Depression
Bottom Line
View on ClinicalTrials.gov: NCT00086307 ↗Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcome: Primary: Montgomery Asberg Depression Rating Scale (MADRS) — 22.629; 26.102; 29.455 Score on a scale — p=.018
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Pramipexole (Drug); Escitalopram (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- National Institute of Mental Health (NIMH)
- Primary completion
- Mar 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Montgomery Asberg Depression Rating Scale (MADRS) |
22.629; 26.102; 29.455 | .018 sig |
Summary
This study compares the effectiveness of the combination of antidepressants: Lexapro and Pramipexole, with the effectiveness of each antidepressant alone.
Purpose: Patients between 18 and 65 years of age with Major Depressive Disorder without psychotic features may be eligible for this 9-week study. Candidates must currently be in a major depressive episode of at least 4 weeks' duration, have failed to respond to treatment with an SSRI (Prozac, Zoloft, Paxil, Luvox, Celexa), and not have failed to respond to more than four antidepressants for the current episode. Candidates are screened with a physical examination, psychiatric evaluation, blood tests, review of vital signs, height and weight measurements, electrocardiogram (ECG), urine test for illegal drugs, and pregnancy test for women.
Participants are tapered off antidepressants or other medications prohibited during the study and remain drug-free for 1 week before starting treatment. They are then randomly assigned to take pramipexole and escitalopram, pramipexole alone, or escitalopram alone for 6 weeks. During the study, participants come to the clinic eight times for health assessments and symptoms assessments, which include a check of vital signs and rating scales for depression and anxiety, adverse events, and sexual functioning. Blood and urine samples are collected periodically to monitor health, detect pregnancy in women, and detect illicit drug use.
At the end of the 6-week treatment period, participants have a physical examination, ECG, blood test, and check of vital signs. Short-term anti-depressant treatment is offered, and plans are made for long-term treatment.
Atendemos pacientes de habla hispana.
...
Eligibility Criteria
INCLUSION CRITERIA
- Male or female subjects, 18 to 65 years of age.
- Female subjects of childbearing potential must be using a medically accepted means of contraception.
- Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document.
- Subjects must fulfill DSM-IV criteria for Major Depression (296.33) without psychotic features, based on clinical assessment and confirmed by a structured diagnostic interview, SCID-P.
- Subjects must have an initial score of greater than or equal to 20 on the MADRS at Visit 1 and Visit 2.
- Subjects must not have a greater than a 25% decrease in the MADRS total scores during washout (between Visits 1 and 2).
- Current or past history of lack of response to at least one adequate antidepressant trial (SSRI) operationally defined using the Antidepressant Treatment History Form (ATHF) (Sackeim 2001b). If this criteria has not been met, a four-week prospective trial of a standard antidepressant (at the patients' and clinicians' discretion) may be given. Subjects are excluded if greater than four failed antidepressant trials for the current major depressive (adequate dose and duration as defined by the ATHF).
- Current major depressive episode of at least 4 weeks duration.
EXCLUSION CRITERIA
- Presence of psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder or bipolar disorder as defined in the DSM-IV.
- Subjects with a history of DSM-IV drug or alcohol dependency or abuse (except for nicotine or caffeine) within the preceding 3 months.
- Previously failed to respond to an adequate trial (dose and duration) of escitalopram.
- Female subjects who are either pregnant or nursing.
- Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
- Subjects with uncorrected hypothyroidism or hyperthyroidism.
- Subjects with one or more seizures without a clear and resolved etiology.
- Previous treatment with pramipexole.
- Treatment with a reversible MAOI within 2 weeks prior to Visit 2.
- Treatment with fluoxetine within 5 weeks prior to Visit 2.
- Treatment with any other concomitant medication not allowed (Appendix A) 7 days prior to study Visit 2.
- Treatment with clozapine or ECT within 3 months prior to study Visit 2.
- Judged clinically to be an acute suicidal risk.
- Psychotherapy will not be permitted during the study.
Data sourced from ClinicalTrials.gov (NCT00086307). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.